Login to Your Account

Alnylam, Sanofi embark on late-stage trials of fitusiran

By Michael Fitzhugh
Staff Writer

Friday, July 7, 2017

An antithrombin-targeting RNAi therapy for hemophilia, fitusiran, developed by Alnylam Pharmaceuticals Inc. with Sanofi Genzyme, is entering phase III territory.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription